The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
The Biden team's second-quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
See which stocks are posting big moves after the bell on July 16.Market Insiderread more
United Airlines' second-quarter profit tops estimates but questions about the 737 Max linger.Airlinesread more
Three civil rights groups filed a federal lawsuit on Tuesday challenging the Trump administration's new asylum rule, which bars asylum claims from most noncitizens who travel...Politicsread more
Google VP of policy Karan Bhatia started sweating early as hearing chair Ted Cruz brings out an internal presentation created within the company.Technologyread more
At a hearing with the House Judiciary subcommittee on antitrust, an Amazon representative disputed a key argument about how it users sellers' data.Technologyread more
Charles Evans spoke Tuesday at CNBC's @Work Human Capital + Finance Conference in Chicago. The Fed president said he is worried about low inflation and several other issues.At Workread more
Jim Cramer just doesn't get it. He thinks the market is really confused about commodity prices and wouldn't know a good thing even when it bit it in the face. Heck, just look at the airlines flying high right now!
Yet again on Thursday, both the and Dow Jones ended in the red when the price of crude oil collapsed to $43. At this point, Cramer has stated the benefits to low oil prices so many times he's turning blue in the face.
"With commodity prices down and down big, as they are now, that gives you a benign market, a positive one, less roiled by a host of earnings disappointments and interest rate hikes that can slay any bull, even a raging one," the "Mad Money" host added.
Cramer saw the same thing occur back in 2008, and while it is painfully clear that commodity spikes contributed to the two largest market crashes of his lifetime; for some reason people still question if cheap oil prices are a good thing.
The "Mad Money" host has exhausted himself talking about the benefits. How small businesses and investors now have expendable income to go out to dinner, or hire more. Even the airline industry has made a major comeback because of crude.
Read More Cramer: We've got the market all wrong
Cramer has always had the goal of alerting investors when an incredible opportunity reveals itself. He knows how to spot the stocks that keep heading higher without any end in sight.
For instance, the $2.3 billion drug developer Esperion Therapeutics has been on a tear lately as investors anticipate its pill that is designed to lower levels of bad cholesterol in patients who are unable to take traditional statins.
Could this stock head even higher in 2015? To find out, Cramer spoke with Esperion CEO Tim Mayleben.
"I don't know the explanation for the stock activity for sure, but we are very excited about the drug that we are developing. It's got a particularly unsexy name…but we think it's one of the most attractive drugs in development," Mayleben said.
Now that the Fed meeting is over, Cramer can finally breathe easier. However amid a volatile market on Thursday that ended in the red, could the bounce back?
Garner indicated that while the S&P has suffered weakness recently, this is only a temporary stop on its way back up. She thinks that the market is not overbought or oversold, it's right in the middle.
Thus Garner believes that the S&P will head higher, all the way up to 2170 or 2180. At that point, she recommends doing some profit taking.
Cramer has had his eye on technology this year and sometimes in order to stay ahead of the trends that means going off the tape to talk to innovative companies.
On Wednesday, Starbucks announced plans to roll out an on-demand delivery service through its mobile app. The delivery service was made possible thanks to a partnership with Postmates, which allows you to order anything from any store and they will deliver it to you under an hour for a small fee.
Last year Postmates was only in five cities, and now they have grown into 22 markets across the U.S. with the goal of 50 by the end of the year.
Will the deal with Starbucks take Postmates to another level? To find out, Cramer spoke with its co-founder and CEO Bastian Lehmann.
"Starbucks and Postmates…Wow! We are crazy in the office still. It was such a big day yesterday and we have been working on this for months but to be able to talk about it, and the trust we received from Starbucks is incredible for us," Lehmann said.
Another company on Cramer's radar is Platform Specialty Products Corp. In 2013 it was started by Martin Franklin, the founder of Jarden. He started the venture with the backing of activist Bill Ackman, whose Pershing Square fund owns more than 20 percent.
Since that time Platform has made a series of chemical company acquisitions, with the most recent large deal to acquire Arysta Lifescience for approximately $3.51 billion. Even the stock is up 54 percent since it listed on the NYSE with a 16 percent rally year to date.
With all of its acquisitions and equity offerings, has Platform raised all of the cash it needs? To find out, Cramer sat down with Platform Specialty Products CEO Dan Leever.
"We have all the money we need right now, but the next big deal that we do will require raising more equity for sure," Leever said.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
Biocryst Pharmaceuticals: "I'm not going to go with that one, because that's been knocking around for a long time with enzyme specialty pharma. It doesn't have what I want, which are these big phase three drugs that are about to go on the market."
Duke Energy Corp: "All the utilities have been slammed here over the false fears that the Fed is going to instantly start raising rates. I'm going to say that I like Duke, but I see you and raise you with Dominion. "